LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.13 -2.59

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.13

Max

1.18

Belangrijke statistieken
By Trading Economics
Inkomsten	614K -6.5M
Werknemers	37

Dividenden
By Dow Jones
Volgende Winsten	30 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 83M
Vorige openingsprijs	3.72
Vorige sluitingsprijs	1.13

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mrt 2026, 23:39 UTC

Populaire aandelen

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mrt 2026, 23:20 UTC

Winsten

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mrt 2026, 21:43 UTC

Winsten

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mrt 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mrt 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mrt 2026, 23:24 UTC

Marktinformatie

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mrt 2026, 22:30 UTC

Winsten

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mrt 2026, 22:30 UTC

Winsten

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mrt 2026, 22:30 UTC

Winsten

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mrt 2026, 22:13 UTC

Winsten

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mrt 2026, 22:13 UTC

Winsten

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mrt 2026, 22:13 UTC

Winsten

Vermilion Energy 4Q EPS C$2.86 >VET

4 mrt 2026, 22:04 UTC

Marktinformatie

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mrt 2026, 21:53 UTC

Winsten

Lithium Americas 4Q Rev $66.8M >LAC

4 mrt 2026, 21:53 UTC

Winsten

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mrt 2026, 21:52 UTC

Winsten

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mrt 2026, 21:50 UTC

Winsten

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mrt 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 mrt 2026, 21:48 UTC

Winsten

Webull 4Q Rev $165.2M >BULL

4 mrt 2026, 21:48 UTC

Winsten

Webull 4Q EPS 1c >BULL

4 mrt 2026, 21:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 mrt 2026, 21:45 UTC

Marktinformatie

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mrt 2026, 21:40 UTC

Winsten

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mrt 2026, 21:36 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mrt 2026, 21:27 UTC

Winsten

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mrt 2026, 21:17 UTC

Marktinformatie

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mrt 2026, 21:16 UTC

Winsten

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mrt 2026, 21:15 UTC

Winsten

Broadcom 1Q EPS $1.50 >AVGO

4 mrt 2026, 21:15 UTC

Winsten

Broadcom 1Q Net $7.35B >AVGO

4 mrt 2026, 21:15 UTC

Winsten

Broadcom 1Q Rev $19.31B >AVGO

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.